Hanmi Pharmaceutical presented the results of LAPSLrhGH domestic phase I clinical trial and global phase Ⅱ clinical trial at the 97th Endocrine Society (ENDO).
Hanmi Pharmaceutical (www.hanmipharm.com) LAPSrhGH under development was announced at one of the most famous conferences.
On March 9, Hanmi(President & CEO LEE, Gwansun) announced it presented the interim results of LAPSrhGH’s domestic phase I clinical trial and global phase Ⅱ clinical trial at the 97th Endocrine Society (ENDO) held from Mar. 3 to Mar 8 in San Diego.
LAPSLrhGH as a cure for lack of Sustained Release-human Growth Hormone(SR-hGH) is applied by the Hanmi’s LAPSCOVERY technology which enhances significantly the effects of bio medicines and extends the interval of injection into more than a week. It relives the pain of patients when it was injected.
According to the presentation, Hanmi Pharmaceutical confirmed the more-than-a-week-long duration of medicinal effects and safety when LAPSLrhGH was injected one-time in phase I clinical trial on Korean healthy adult males.
In addition, on-going phase Ⅱ clinical trial on those adults with SR-hGH deficiency in 22 medical centers in Korean and eight eastern European countries showed the safety, duration of medicinal effects and proper dosage for future development of LAPSLrhGH.
“LAPSLrhGH extends the interval of injection into more than a week than conventional medicines and alleviate patients’ injection pain, which is expected to enhance the level of patient’s quality of living,” Kang Ja-hun, director manager of Hanmi’s clinical trial department, “We will make the utmost efforts to provide innovative cures for those adult patients with growth hormone deficiency and childhood patients suffering from dwarfism.”
(Note) The Endocrine Society(ENDO) is the oldest and largest endocrine society in the world, which is held in major cities in the U.S. and marking the 97th this year.
By Lee Jae-seung